Pfizer's new cancer combo shows early promise but trial halted
NCT ID NCT06285097
First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This early-stage trial tested a new drug, PF-07820435, alone or with another immunotherapy (sasanlimab) in 9 people with advanced solid tumors like lung, skin, or kidney cancer. The main goals were to check safety and find the right dose. The study was terminated early, so results are limited.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
PF-07820435 (immune agonist) and sasanlimab (PD-1 blocker)
What this could lead to
If it works, this could point toward a new treatment option for advanced solid tumors like lung or skin cancer.
What could go wrong
This is a very early Phase 1 trial with only 9 participants, now terminated. It was designed to find safe doses, not to prove effectiveness. Many early cancer drugs fail to show benefit.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Corewell Health (reference non-engagement letter)
Grand Rapids, Michigan, 49503, United States
-
Florida Cancer Specialists Sarasota Drug Development Unit
Sarasota, Florida, 34232, United States
-
Hospital Oncologico Dr. Isaac Gonzalez-Martinez
Rio Piedras, 00935, Puerto Rico
-
National Cancer Center Hospital East
Kashiwa, Chiba, 277-8577, Japan
-
Pan American Center for Oncology Trials, LLC
Rio Piedras, 00935, Puerto Rico
-
SCRI Oncology Partners
Nashville, Tennessee, 37203, United States
-
START Midwest
Grand Rapids, Michigan, 49546, United States
-
Sarah Cannon Research Institute - Pharmacy
Nashville, Tennessee, 37203, United States
-
The Cancer Institute Hospital of JFCR
Koto, Tokyo, 135-8550, Japan
-
Tristar Centennial Medical Center
Nashville, Tennessee, 37203, United States